

Andrew J Mcmichael

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6750811/publications.pdf>

Version: 2024-02-01

191
papers

34,252
citations

6613

79
h-index

3579

181
g-index

200
all docs

200
docs citations

200
times ranked

20637
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature, 1998, 391, 795-799.	27.8	1,983
2	Common West African HLA antigens are associated with protection from severe malaria. Nature, 1991, 352, 595-600.	27.8	1,494
3	Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Medicine, 2002, 8, 379-385.	30.7	1,432
4	Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA. Science, 1998, 279, 2103-2106.	12.6	1,340
5	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science, 2007, 317, 944-947.	12.6	1,136
6	Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Medicine, 1997, 3, 212-217.	30.7	1,096
7	Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature, 1991, 354, 453-459.	27.8	1,060
8	Cytotoxic T-Cell Immunity to Influenza. New England Journal of Medicine, 1983, 309, 13-17.	27.0	918
9	Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature, 2001, 410, 106-111.	27.8	910
10	Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nature Medicine, 2012, 18, 274-280.	30.7	882
11	HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function. Journal of Experimental Medicine, 2000, 192, 63-76.	8.5	820
12	The immune response during acute HIV-1 infection: clues for vaccine development. Nature Reviews Immunology, 2010, 10, 11-23.	22.7	707
13	Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature, 1992, 360, 434-439.	27.8	638
14	Rapid Effector Function in CD8+ Memory T Cells. Journal of Experimental Medicine, 1997, 186, 859-865.	8.5	626
15	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1253-1272.	8.5	562
16	Surface Expression of HLA-E, an Inhibitor of Natural Killer Cells, Enhanced by Human Cytomegalovirus gpUL40. Science, 2000, 287, 1031-1033.	12.6	554
17	Cellular immune responses to HIV. Nature, 2001, 410, 980-987.	27.8	550
18	HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature, 1988, 336, 484-487.	27.8	471

#	ARTICLE	IF	CITATIONS
19	Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. <i>Nature Medicine</i> , 1996, 2, 906-911.	30.7	469
20	The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. <i>European Journal of Immunology</i> , 1997, 27, 1164-1169.	2.9	442
21	Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. <i>Nature</i> , 1994, 369, 403-407.	27.8	438
22	Crystal structure of the complex between human CD8 $\alpha\beta$ and HLA-A2. <i>Nature</i> , 1997, 387, 630-634.	27.8	428
23	Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27-Restricted Cytotoxic T Lymphocyte Responses. <i>Journal of Experimental Medicine</i> , 2001, 193, 375-386.	8.5	424
24	Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. <i>Nature</i> , 1987, 326, 881-882.	27.8	420
25	Presentation of viral antigen controlled by a gene in the major histocompatibility complex. <i>Nature</i> , 1990, 345, 449-452.	27.8	379
26	HLA-E is expressed on trophoblast and interacts with CD94 α /NKG2 receptors on decidual NK cells. <i>European Journal of Immunology</i> , 2000, 30, 1623-1631.	2.9	379
27	Common Genetic Variation and the Control of HIV-1 in Humans. <i>PLoS Genetics</i> , 2009, 5, e1000791.	3.5	377
28	Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. <i>Journal of Clinical Investigation</i> , 2008, 118, 3478-90.	8.2	373
29	HIV-1-Specific Mucosal CD8+ Lymphocyte Responses in the Cervix of HIV-1-Resistant Prostitutes in Nairobi. <i>Journal of Immunology</i> , 2000, 164, 1602-1611.	0.8	361
30	Antigenic oscillations and shifting immunodominance in HIV-1 infections. <i>Nature</i> , 1995, 375, 606-611.	27.8	342
31	A human lymphocyte-associated antigen involved in cell-mediated lympholysis. <i>European Journal of Immunology</i> , 1983, 13, 202-208.	2.9	315
32	ESCAPE OF HUMAN IMMUNODEFICIENCY VIRUS FROM IMMUNE CONTROL. <i>Annual Review of Immunology</i> , 1997, 15, 271-296.	21.8	315
33	Escape from the Dominant HLA-B27-Restricted Cytotoxic T-Lymphocyte Response in Gag Is Associated with a Dramatic Reduction in Human Immunodeficiency Virus Type 1 Replication. <i>Journal of Virology</i> , 2007, 81, 12382-12393.	3.4	299
34	A structural basis for immunodominant human T cell receptor recognition. <i>Nature Immunology</i> , 2003, 4, 657-663.	14.5	290
35	Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen. <i>Journal of Virology</i> , 1999, 73, 7524-7532.	3.4	288
36	A New Look at T Cells. <i>Journal of Experimental Medicine</i> , 1998, 187, 1367-1371.	8.5	265

#	ARTICLE	IF	CITATIONS
37	Broadly targeted CD8 ⁺ T cell responses restricted by major histocompatibility complex E. Science, 2016, 351, 714-720.	12.6	260
38	Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing. PLoS ONE, 2010, 5, e12303.	2.5	259
39	TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Current Biology, 1998, 8, 1-10.	3.9	258
40	HIV VACCINES. Annual Review of Immunology, 2006, 24, 227-255.	21.8	257
41	Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen. Journal of Immunology, 2000, 164, 4968-4978.	0.8	247
42	Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine. PLoS ONE, 2007, 2, e984.	2.5	247
43	HIV vaccines 1983–2003. Nature Medicine, 2003, 9, 874-880.	30.7	240
44	Induction of Fas Ligand Expression by HIV Involves the Interaction of Nef with the T Cell Receptor α Chain. Journal of Experimental Medicine, 1999, 189, 1489-1496.	8.5	231
45	Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1422-1431.	5.6	229
46	Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8 + T-Cell Epitopes. Journal of Virology, 2006, 80, 4717-4728.	3.4	220
47	Functions of nonclassical MHC and non-MHC-encoded class I molecules. Current Opinion in Immunology, 1999, 11, 100-108.	5.5	207
48	A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. Journal of General Virology, 2004, 85, 911-919.	2.9	206
49	Evasion of Cytotoxic T Lymphocyte (CTL) Responses by Nef-dependent Induction of Fas Ligand (CD95L) Expression on Simian Immunodeficiency Virus–infected Cells. Journal of Experimental Medicine, 1997, 186, 7-16.	8.5	199
50	Characterization of the CD4+ T Cell Response to Epstein-Barr Virus during Primary and Persistent Infection. Journal of Experimental Medicine, 2003, 198, 903-911.	8.5	199
51	Structural Features Impose Tight Peptide Binding Specificity in the Nonclassical MHC Molecule HLA-E. Molecular Cell, 1998, 1, 531-541.	9.7	190
52	Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.. Nature Medicine, 2000, 6, 951-955.	30.7	190
53	Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. Journal of Clinical Investigation, 2001, 107, 341-349.	8.2	190
54	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Molecular Therapy, 2014, 22, 464-475.	8.2	188

#	ARTICLE	IF	CITATIONS
55	MEDICINE: Enhanced: The Need for a Global HIV Vaccine Enterprise. Science, 2003, 300, 2036-2039.	12.6	186
56	Immune responses in HIV-exposed seronegatives: have they repelled the virus?. Current Opinion in Immunology, 1995, 7, 448-455.	5.5	183
57	Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nature Immunology, 2009, 10, 636-646.	14.5	170
58	T Cell Cross-Reactivity and Conformational Changes during TCR Engagement. Journal of Experimental Medicine, 2004, 200, 1455-1466.	8.5	159
59	Bound Water Structure and Polymorphic Amino Acids Act Together to Allow the Binding of Different Peptides to MHC Class I HLA-B53. Immunity, 1996, 4, 215-228.	14.3	155
60	The T-Cell Response to HIV. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007054-a007054.	6.2	155
61	Oligoclonal Expansions of CD8+ T Cells in Chronic HIV Infection Are Antigen Specific. Journal of Experimental Medicine, 1998, 188, 785-790.	8.5	153
62	HIV-Host Interactions: Implications for Vaccine Design. Cell Host and Microbe, 2016, 19, 292-303.	11.0	143
63	Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. Journal of Virology, 2011, 85, 10518-10528.	3.4	141
64	Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. Aids, 2000, 14, 225-233.	2.2	140
65	Antagonist HIV-1 Gag Peptides Induce Structural Changes in HLA B8. Journal of Experimental Medicine, 1996, 184, 2279-2286.	8.5	136
66	T Cell Responses and Viral Escape. Cell, 1998, 93, 673-676.	28.9	127
67	Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. Science Immunology, 2016, 1, aag0851.	11.9	120
68	Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. Journal of General Virology, 2007, 88, 1-12.	2.9	118
69	An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nature Immunology, 2022, 23, 50-61.	14.5	110
70	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Molecular Therapy, 2016, 24, 832-842.	8.2	107
71	BirA Enzyme: Production and Application in the Study of Membrane Receptor-Ligand Interactions by Site-Specific Biotinylation. Analytical Biochemistry, 1999, 266, 9-15.	2.4	104
72	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. Blood, 1999, 93, 1506-1510.	1.4	104

#	ARTICLE	IF	CITATIONS
73	HIV-specific Cytotoxic T Cells from Long-Term Survivors Select a Unique T Cell Receptor. Journal of Experimental Medicine, 2004, 200, 1547-1557.	8.5	103
74	Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nature Communications, 2016, 7, 11660.	12.8	103
75	Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. European Journal of Immunology, 2005, 35, 341-351.	2.9	99
76	Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine, 1999, 17, 589-596.	3.8	97
77	Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nature Immunology, 2006, 7, 179-189.	14.5	91
78	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. PLoS Pathogens, 2011, 7, e1001273.	4.7	90
79	Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunology Letters, 1999, 66, 177-181.	2.5	88
80	Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nature Immunology, 2012, 13, 423-427.	14.5	84
81	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nature Communications, 2018, 9, 1928.	12.8	83
82	Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 Infection. PLoS Pathogens, 2010, 6, e1000893.	4.7	80
83	Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.. Journal of General Virology, 1998, 79, 83-90.	2.9	79
84	The role of HLA-B27 in spondyloarthritis. Immunogenetics, 1999, 50, 220-227.	2.4	78
85	Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors. Journal of Experimental Medicine, 2014, 211, 1273-1280.	8.5	76
86	The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. European Journal of Immunology, 1995, 25, 1927-1931.	2.9	75
87	Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. European Journal of Immunology, 1995, 25, 3270-3276.	2.9	74
88	CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells. Cell Reports, 2020, 30, 137-152.e5.	6.4	74
89	Vaccines that stimulate T cell immunity to HIV-1: the next step. Nature Immunology, 2014, 15, 319-322.	14.5	72
90	A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. Journal of General Virology, 2002, 83, 75-80.	2.9	72

#	ARTICLE	IF	CITATIONS
91	Peptide selection by class I molecules of the major histocompatibility complex. <i>Current Biology</i> , 1993, 3, 854-866.	3.9	71
92	Design and Validation of an Enzyme-Linked Immunospot Assay for Use in Clinical Trials of Candidate HIV Vaccines. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 611-618.	1.1	70
93	Ex Vivo Phenotype and Frequency of Influenza Virus-Specific CD4 Memory T Cells. <i>Journal of Virology</i> , 2004, 78, 7284-7287.	3.4	67
94	High Levels of Virus-Specific CD4 ⁺ T Cells Predict Severe Pandemic Influenza A Virus Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1292-1297.	5.6	64
95	Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinants. <i>European Journal of Immunology</i> , 1981, 11, 694-699.	2.9	63
96	HIV/AIDS: HLA Leaves Its Footprints on HIV. <i>Science</i> , 2002, 296, 1410-1411.	12.6	62
97	Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges. <i>PLoS Pathogens</i> , 2011, 7, e1002041.	4.7	62
98	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. <i>JCI Insight</i> , 2017, 2, e91868.	5.0	59
99	An Early HIV Mutation within an HLA-B*57-Restricted T Cell Epitope Abrogates Binding to the Killer Inhibitory Receptor 3DL1. <i>Journal of Virology</i> , 2011, 85, 5415-5422.	3.4	57
100	Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. <i>Nature Communications</i> , 2018, 9, 3137.	12.8	57
101	Effects of monoclonal antibodies to the α and β chains of the human lymphocyte function-associated (H-LFA-1) antigen on T lymphocyte functions. <i>European Journal of Immunology</i> , 1985, 15, 888-892.	2.9	54
102	Cytotoxic T cell abundance and virus load in human immunodeficiency virus type 1 and human T cell leukaemia virus type 1. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2001, 268, 1215-1221.	2.6	54
103	Requirement of the Proteasome for the Trimming of Signal Peptide-derived Epitopes Presented by the Nonclassical Major Histocompatibility Complex Class I Molecule HLA-E. <i>Journal of Biological Chemistry</i> , 2003, 278, 33747-33752.	3.4	54
104	The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques. <i>Journal of Immunology</i> , 2018, 200, 49-60.	0.8	54
105	Cytotoxic T Lymphocytes Specific for Influenza Virus. <i>Current Topics in Microbiology and Immunology</i> , 1994, 189, 75-91.	1.1	53
106	Class I cross-restricted T cells reveal low responder allele due to processing of viral antigen. <i>Nature</i> , 1989, 337, 653-655.	27.8	52
107	Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pThr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. <i>Vaccine</i> , 2008, 26, 6671-6677.	3.8	50
108	Identification of T cell receptor recognition residues for a viral peptide presented by HLA B27. <i>European Journal of Immunology</i> , 1994, 24, 2357-2363.	2.9	49

#	ARTICLE	IF	CITATIONS
109	Casting a wider net: Immunosurveillance by nonclassical MHC molecules. PLoS Pathogens, 2019, 15, e1007567.	4.7	49
110	Contribution of proteasome-catalyzed peptide<i>cis</i>-splicing to viral targeting by CD8⁺T cells in HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24748-24759.	7.1	48
111	Epitope specificity of clonally expanded populations of CD8+ T cells found within the joints of patients with inflammatory arthritis. Arthritis and Rheumatism, 2001, 44, 2038-2045.	6.7	40
112	Lack of Truncated IFITM3 Transcripts in Cells Homozygous for the rs12252-C Variant That is Associated With Severe Influenza Infection. Journal of Infectious Diseases, 2018, 217, 257-262.	4.0	40
113	Homocysteine modification of HLA antigens and its immunological consequences. European Journal of Immunology, 1996, 26, 1443-1450.	2.9	39
114	Characterization of the HLA-A2.2 subtype: T cell evidence for further heterogeneity. Immunogenetics, 1985, 21, 11-23.	2.4	38
115	Mechanisms of Protection Induced by Attenuated Simian Immunodeficiency Virus II. Lymphocyte Depletion Does Not Abrogate Protection. AIDS Research and Human Retroviruses, 1998, 14, 1187-1198.	1.1	38
116	Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals. Journal of Virology, 2011, 85, 3507-3516.	3.4	38
117	Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. PLoS Pathogens, 2016, 12, e1005805.	4.7	36
118	Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. Aids, 2012, 26, 275-284.	2.2	35
119	HLA-Eâ€‘restricted, Gag-specific CD8 ⁺ T cells can suppress HIV-1 infection, offering vaccine opportunities. Science Immunology, 2021, 6, .	11.9	35
120	The original sin of killer T cells. Nature, 1998, 394, 421-422.	27.8	34
121	Is an HIV vaccine possible?. Nature Medicine, 1999, 5, 612-614.	30.7	34
122	Production and crystallization of MHC class I B allele single peptide complexes. FEBS Letters, 1996, 383, 119-123.	2.8	33
123	An antigen processing polymorphism revealed by HLA-B8-restricted cytotoxic T lymphocytes which does not correlate with TAP gene polymorphism. European Journal of Immunology, 1993, 23, 1999-2004.	2.9	32
124	Production, crystallization, and preliminary Xâ€‘ray analysis of the human MHC class Ib molecule HLAâ€‘E. Protein Science, 1998, 7, 1264-1266.	7.6	32
125	Combined structural and immunological refinement of HIV-1 HLA-B8-restricted cytotoxic T lymphocyte epitopes. European Journal of Immunology, 1997, 27, 1515-1521.	2.9	30
126	The arrival of HLA class II tetramers. Journal of Clinical Investigation, 1999, 104, 1669-1670.	8.2	29

#	ARTICLE	IF	CITATIONS
127	First-Class Control of HIV-1. <i>Science</i> , 2010, 330, 1488-1490.	12.6	27
128	The Antiviral Efficacy of HIV-Specific CD8+ T-Cells to a Conserved Epitope Is Heavily Dependent on the Infecting HIV-1 Isolate. <i>PLoS Pathogens</i> , 2011, 7, e1001341.	4.7	26
129	Differential processing of influenza nucleoprotein in human and mouse cells. <i>European Journal of Immunology</i> , 1998, 28, 625-635.	2.9	25
130	The dynamics of the cellular immune response to HIV infection: implications for vaccination. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2000, 355, 1007-1011.	4.0	24
131	A review of vaccines for HIV prevention. <i>Journal of Gene Medicine</i> , 2003, 5, 3-10.	2.8	24
132	Induction of long-lasting multi-specific CD8+T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. <i>European Journal of Immunology</i> , 2006, 36, 2574-2584.	2.9	24
133	Detailed and atypical HLA-E peptide binding motifs revealed by a novel peptide exchange binding assay. <i>European Journal of Immunology</i> , 2020, 50, 2075-2091.	2.9	24
134	Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN- γ ELISPOT assay. <i>European Journal of Immunology</i> , 2009, 39, 975-985.	2.9	23
135	Evidence for the persistence of monoclonal expansions of CD8+ T cells following primary simian immunodeficiency virus infection. <i>European Journal of Immunology</i> , 1998, 28, 1172-1180.	2.9	22
136	Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101+ patients protected mice against chimaeric ecotropic HIV-1 challenge. <i>European Journal of Immunology</i> , 2009, 39, 1831-1840.	2.9	22
137	Identification of novel HIV-1-derived HLA-E-binding peptides. <i>Immunology Letters</i> , 2018, 202, 65-72.	2.5	21
138	New templates for HIV-1 antibody-based vaccine design. <i>F1000 Biology Reports</i> , 2010, 2, 60.	4.0	20
139	HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. <i>Molecular Therapy</i> , 2017, 25, 494-503.	8.2	19
140	Importance of a conserved TCR J α -encoded tyrosine for T cell recognition of an HLA B27/ peptide complex. <i>European Journal of Immunology</i> , 1998, 28, 2704-2713.	2.9	18
141	Lysis of allogeneic human lymphocytes by nonspecifically activated T-like cells. <i>European Journal of Immunology</i> , 1982, 12, 1002-1005.	2.9	17
142	Selection of T cell receptor variable gene-encoded amino acids on the third binding site loop: a factor influencing variable chain selection in a T cell response. <i>European Journal of Immunology</i> , 1995, 25, 1529-1534.	2.9	17
143	Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. <i>Clinical Infectious Diseases</i> , 2015, 61, 120-128.	5.8	17
144	Capturing the antigen landscape: HLA-E, CD1 and MR1. <i>Current Opinion in Immunology</i> , 2019, 59, 121-129.	5.5	17

#	ARTICLE	IF	CITATIONS
145	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. <i>Blood</i> , 1999, 93, 1506-1510.	1.4	16
146	Maintenance of MHC polymorphism. <i>Nature</i> , 1992, 355, 403-403.	27.8	15
147	Triple bypass: complicated paths to HIV escape. <i>Journal of Experimental Medicine</i> , 2007, 204, 2785-2788.	8.5	15
148	Natural selection at work on the surface of virus-infected cells. <i>Science</i> , 1993, 260, 1771-1772.	12.6	14
149	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. <i>Communications Biology</i> , 2022, 5, 271.	4.4	14
150	A cross-species functional interaction between the murine major histocompatibility complex class I β 3 domain and human CD8 revealed by peptide-specific cytotoxic T lymphocytes. <i>European Journal of Immunology</i> , 1992, 22, 1643-1646.	2.9	13
151	Expression and function of HLA-B27 in lipid-linked form: Implications for cytotoxic T lymphocyte-induced apoptosis signal transduction. <i>European Journal of Immunology</i> , 1993, 23, 653-658.	2.9	12
152	Effects of Retroviral Protease Inhibitors on Proteasome Function and Processing of HIV-Derived MHC Class I-Restricted Cytotoxic T Lymphocyte Epitopes. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1063-1066.	1.1	12
153	AIDS/HIV: Finding Footprints Among the Trees. <i>Science</i> , 2007, 315, 1505-1507.	12.6	12
154	Preexisting compensatory amino acids compromise fitness costs of a HIV-1 Δ T cell escape mutation. <i>Retrovirology</i> , 2014, 11, 101.	2.0	12
155	Unusual antigen presentation offers new insight into HIV vaccine design. <i>Current Opinion in Immunology</i> , 2017, 46, 75-81.	5.5	12
156	Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029124.	5.5	12
157	Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. <i>PLoS ONE</i> , 2014, 9, e114709.	2.5	11
158	Why the long latent period?. <i>Nature</i> , 1990, 348, 388-388.	27.8	10
159	Cytotoxic T Lymphocytes: Specificity, Surveillance, and Escape. <i>Advances in Cancer Research</i> , 1992, 59, 227-244.	5.0	10
160	T cell receptor usage in infectious disease. <i>Seminars in Immunopathology</i> , 1999, 21, 37-54.	4.0	10
161	Role of class I molecules of the major histocompatibility complex in cytotoxic T-cell function in health and disease. <i>Seminars in Immunopathology</i> , 1992, 14, 1-16.	4.0	9
162	Cytotoxic T lymphocytes and immune surveillance. <i>Cancer Surveys</i> , 1992, 13, 5-21.	1.5	9

#	ARTICLE	IF	CITATIONS
163	HLA B27: a disease-associated immune response gene. Research in Immunology, 1991, 142, 475-482.	0.9	8
164	Reversion and T Cell Escape Mutations Compensate the Fitness Loss of a CD8+ T Cell Escape Mutant in Their Cognate Transmitted/Founder Virus. PLoS ONE, 2014, 9, e102734.	2.5	8
165	Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes. Cell Reports, 2022, 39, 110959.	6.4	8
166	Nosing ahead in the cold war. Nature, 1990, 344, 16-16.	27.8	7
167	Engagement of a T cell receptor by major histocompatibility complex irrespective of peptide. European Journal of Immunology, 1997, 27, 879-885.	2.9	7
168	Legacy of the influenza pandemic 1918: The host T cell response. Biomedical Journal, 2018, 41, 242-248.	3.1	6
169	Interrogating the recognition landscape of a conserved HIV-specific TCR reveals distinct bacterial peptide cross-reactivity. ELife, 2020, 9, .	6.0	6
170	Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. Journal of Clinical Investigation, 2021, 131, .	8.2	6
171	How viruses hide from T cells. Trends in Microbiology, 1997, 5, 211-212.	7.7	5
172	Influenza vaccines: mTOR inhibition surprisingly leads to protection. Nature Immunology, 2013, 14, 1205-1207.	14.5	5
173	Introduction: Presentation of viral antigens to cytotoxic T cells. Seminars in Virology, 1996, 7, 1-2.	3.9	4
174	Topological perspective on HIV escape. Science, 2019, 364, 438-439.	12.6	4
175	GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans. Journal of Experimental Medicine, 2022, 219, .	8.5	4
176	From influenza to HIV and back?. Nature Immunology, 2007, 8, 1149-1151.	14.5	3
177	Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. Journal of Virology, 2018, 92, .	3.4	3
178	The Importance of Cellular Immune Response to HIV: Implications for Antibody Production and Vaccine Design. DNA and Cell Biology, 2021, , .	1.9	3
179	Tamarin compatibility. Nature, 1990, 346, 17-17.	27.8	2
180	A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology, 2017, 14, 46.	2.0	2

#	ARTICLE	IF	CITATIONS
181	T cell receptor usage in infectious disease. <i>Seminars in Immunopathology</i> , 1999, 21, 37-54.	4.0	2
182	Recognition of viral antigens at the cell surface. <i>Cancer Surveys</i> , 1995, 22, 51-62.	1.5	2
183	Simplification of two-dimensional gel patterns of HLA class II antigens. <i>Tissue Antigens</i> , 1986, 28, 72-83.	1.0	1
184	HIV-1 Vaccines: Let's Get Physical. <i>Immunity</i> , 2013, 38, 410-413.	14.3	1
185	Ita Askonas and her influence in the field of antigen presentation. <i>Current Opinion in Immunology</i> , 2014, 26, 111-114.	5.5	1
186	Effects Of A Monoclonal Antibody To Human Platelet Glycoprotein I On Platelet - Von Willebrand Factor Subendothelium Interactions. <i>Thrombosis and Haemostasis</i> , 1981, 46, 0297.	3.4	0
187	Immune Escape in Hiv Infection. <i>Clinical Science</i> , 1995, 88, 31P-31P.	0.0	0
188	Identification and Characterisation of Derp1-Specific CD8+ T Cells in the Peripheral Blood of Atopic Individuals. <i>Clinical Science</i> , 2002, 103, 2P-2P.	0.0	0
189	The use of tetramers in the quantitative analysis of T-cell responses. <i>Methods in Microbiology</i> , 2002, , 125-156.	0.8	0
190	Brigitte Alice Askonas. 1 April 1923â€”9 January 2013. <i>Biographical Memoirs of Fellows of the Royal Society</i> , 2018, 65, 31-45.	0.1	0
191	Gut microbiota induce local and systemic CD4 T cell responses in healthy individuals that are altered in inflammatory bowel diseases. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, .	0.5	0